相変化物質（PCM）市場調査レポート：2028年までの予測

出版：Market Research Future（マーケットリサーチフューチャー）　出版年月：2022年5月

Phase change material Market Research Report Forecast till 2028
相変化物質（PCM）市場調査レポート：2028年までの予測

レポート目次　　お問合せ・ご注文　　価格・納期について

Market Research Future（マーケットリサーチフューチャー）「相変化物質（PCM）市場調査レポート：2028年までの予測 – Phase change material Market Research Report Forecast till 2028」は世界の相変化物質（PCM）市場を調査し、主要地域別分析や関連企業情報などを掲載しています。

Market Overview

The phase change material market size is projected to witness a notable market expansion at a CAGR of 17.90% during the review period to surpass USD 49,021.39 thousand by the end of 2028. PCMs are bio-based materials, for example, unsaturated fats or oils that are utilized as a shell material for drug conveyance. Phase change materials are inexhaustible, reusable, and motor and fuel free, making them ideal for immunization transportation. Phage change materials (PCMs) are substances which assimilate or deliver a lot of supposed ‘inactive’ heat when they go through an adjustment of their actual state, i.e., from strong to fluid as well as the other way around. Offering a scope of warm administration arrangements, PCMs work with the capacity to oversee request between energy prerequisites and utilization.

The global phase change material market is anticipated to register a healthy market expansion during the review period owing to the highest market value of USD 13,397.69 thousand in 2020. In clinical area, the PCMs are widely utilized for transportation of blood, antibodies, and temperature-touchy drugs, surgical tables, hot-cold treatments, treatment of birth asphyxia, and medication conveyance. However, certain impediments related with the item are cooling impact comes from underneath the item, which makes a bigger temperature degree from the highest items to the lower items. Such detriments connected with the utilization of PCM items is a limitation for the market development.

Market Segmentation

The segmental analysis of the global phase change material is classified by type, equipment, temperature range, and end-user.
The type of segment is categorized in terms of Organic, Inorganic, and Eutectic. In terms of equipment the market is classified into Refrigerators, Cold Boxes, and Carriers. By Temperature Range segment the market has been divided into -20 to -35 deg C, 2 to 8 deg C, 10 to 15 deg C, and Others.
The End-user segment of the global phase change material market is segmented as Biopharmaceutical Companies, Hospitals, Medical Laboratories, and Others.

Regional Analysis

Asia-pacific represented the biggest market share and is projected to display a sound CAGR throughout the approaching years. The development of the area can be related with the development of the drug business in China, India, and Japan. Also, the market in North America is powered by admittance to high-esteem drugs, antibody transportation, medical services mindfulness, high per capita consumption on medical care, and the high GDP of the locale. In Europe, the presence of many organizations and SMEs that production and supply phase change materials is supposed to give hopeful development to Europe market. Additionally, The European Health Union executed a methodology in 2020, which incorporates an expansive extent of regions, for example, innovative work of drugs, lab testing, clinical preliminaries, marketing approval, producing, wellbeing innovation evaluation, valuing and repayment, protected innovation insurance, and the section of meds, incorporating generics and biosimilars in the market.

Major Players

The prominent players of the gloal phase change material market is Croda International Plc (UK), PureTemp (US), Sasol (South Africa), Henkel AG & Co. KGaA (Germany), Cryopak (US), Teappcm (US), Rubitherm (Germany), Cold Chain Technologies (US), Merck KGaA (Germany), Pluss Advanced Technologies Pvt. Ltd (India), and PCM Products Ltd (UK).

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

目次

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY 15
1.1 MARKET ATTRACTIVENESS ANALYSIS 17
1.1.1 GLOBAL PHASE CHANGE MATERIALS MARKET, BY TYPE 18
1.1.2 GLOBAL PHASE CHANGE MATERIALS MARKET, BY EQUIPMENT 19
1.1.3 GLOBAL PHASE CHANGE MATERIALS MARKET, BY TEMPERATURE RANGE 20
1.1.4 GLOBAL PHASE CHANGE MATERIALS MARKET, BY END-USER 21
1.1.5 GLOBAL PHASE CHANGE MATERIALS MARKET, BY REGION 22
2 MARKET INTRODUCTION 23
2.1 DEFINITION 23
2.2 SCOPE OF THE STUDY 23
2.3 MARKET STRUCTURE 23
3 RESEARCH METHODOLOGY 24
3.1 RESEARCH PROCESS 24
3.2 PRIMARY RESEARCH 25
3.3 SECONDARY RESEARCH 26
3.4 MARKET SIZE ESTIMATION 26
3.5 TOP-DOWN AND BOTTOM-UP APPROACH 27
3.6 FORECAST MODEL 28
3.7 LIST OF ASSUMPTIONS & LIMITATIONS 29
4 MARKET DYNAMICS 30
4.1 INTRODUCTION 30
4.2 DRIVERS 31
4.2.1 GROWING DEMAND FOR PCMS IN DRUG DELIVERY AND VACCINE AND MEDICINAL TRANSPORT 31
4.2.2 USE OF PCMS FOR THERAPEUTIC HYPOTHERMIA IN NEONATAL AND RHEUMATIC DISEASES 32
4.3 RESTRAINTS 33
4.3.1 DISADVANTAGES ASSOCIATED WITH PCM PRODUCTS 33
4.4 OPPORTUNITIES 34
4.4.1 INCREASING NUMBER OF CLINICAL TRIALS AND DEVELOPMENT OF NEW THERAPIES 34
4.5 CHALLENGES 35
4.5.1 REGULATIONS IN THE COLD SUPPLY CHAIN 35
5 MARKET FACTOR ANALYSIS 36
5.1 SUPPLY CHAIN ANALYSIS 36
5.1.1 RAW MATERIAL SUPPLIERS 37
5.1.1.1 INORGANIC 37
5.1.1.2 ORGANIC 37
5.1.1.3 EUTECTIC 38
5.1.2 PHASE CHANGE MATERIALS PRODUCERS 38
5.1.3 DISTRIBUTION & SALES CHANNEL 38
5.1.4 END-USER 39
5.2 PORTER’S FIVE FORCES ANALYSIS 39
5.2.1 THREAT OF NEW ENTRANTS 40
5.2.2 BARGAINING POWER OF SUPPLIERS 40
5.2.3 THREAT OF SUBSTITUTES 40
5.2.4 BARGAINING POWER OF BUYERS 40
5.2.5 INTENSITY OF RIVALRY 40
5.3 IMPACT OF COVID 19 OUTBREAK ON GLOBAL PHASE CHANGE MATERIALS MARKET 40
5.3.1 IMPACT ON GLOBAL ECONOMY 40
5.3.2 IMPACT ON SUPPLY CHAIN OF PHASE CHANGE MATERIALS MARKET 41
5.3.3 MAJOR GOVERNMENT POLICIES TO COUNTER THE IMPACT OF COVID-19 42
5.3.3.1 MONETARY AND MACRO-FINANCIAL 46
5.3.4 QUALITATIVE ANALYSIS ON CHANGES IN DEMAND FROM END-USERS 47
5.3.4.1 BIOPHARMACEUTICAL COMPANIES 47
5.3.4.2 HOSPITALS 47
5.3.4.3 MEDICAL LABORATORIES 47
6 GLOBAL PHASE CHANGE MATERIALS MARKET, BY TYPE 48
6.1 INTRODUCTION 48
6.2 ORGANIC 49
6.3 INORGANIC 50
6.4 EUTECTIC 51
7 GLOBAL PHASE CHANGE MATERIALS MARKET, BY EQUIPMENT 52
7.1 INTRODUCTION 52
7.2 REFRIGERATORS 53
7.3 COLD BOXES 54
7.4 CARRIERS 55
8 GLOBAL PHASE CHANGE MATERIALS MARKET, BY TEMPERATURE RANGE 56
8.1 INTRODUCTION 56
8.2 -20 TO -35 DEG C 57
8.3 2 TO 8 DEG C 58
8.4 10 TO 15 DEG C 59
8.5 OTHERS 60
9 GLOBAL PHASE CHANGE MATERIALS MARKET, BY END-USER 61
9.1 INTRODUCTION 61
9.2 BIOPHARMACEUTICAL COMPANIES 62
9.3 HOSPITALS 63
9.4 MEDICAL LABORATORIES 64
9.5 OTHERS 65
10 GLOBAL PHASE CHANGE MATERIALS MARKET, BY REGION 66
10.1 INTRODUCTION 66
10.2 NORTH AMERICA 68
10.2.1 US 71
10.2.2 CANADA 73
10.3 EUROPE 75
10.3.1 GERMANY 78
10.3.2 UK 80
10.3.3 FRANCE 82
10.3.4 SPAIN 84
10.3.5 ITALY 86
10.3.6 REST OF EUROPE 88
10.4 ASIA-PACIFIC 90
10.4.1 CHINA 93
10.4.2 INDIA 95
10.4.3 JAPAN 97
10.4.4 SOUTH KOREA 99
10.4.5 REST OF ASIA-PACIFIC 101
10.5 LATIN AMERICA 103
10.5.1 BRAZIL 106
10.5.2 MEXICO 108
10.5.3 ARGENTINA 110
10.5.4 REST OF LATIN AMERICA 112
10.6 MIDDLE EAST & AFRICA 114
10.6.1 GCC COUNTRIES 117
10.6.2 SOUTH AFRICA 119
10.6.3 REST OF THE MIDDLE EAST & AFRICA 121
11 COMPETITIVE LANDSCAPE 123
11.1 INTRODUCTION 123
11.2 MARKET STRATEGY ANALYSIS 123
11.3 COMPETITIVE BENCHMARKING 124
12 COMPANY PROFILES 125
12.1 CRODA INTERNATIONAL PLC 125
12.1.1 COMPANY OVERVIEW 125
12.1.2 FINANCIAL OVERVIEW 126
12.1.3 PRODUCTS OFFERED 126
12.1.4 KEY DEVELOPMENTS 127
12.1.5 SWOT ANALYSIS 127
12.1.6 KEY STRATEGIES 127
12.2 SASOL 128
12.2.1 COMPANY OVERVIEW 128
12.2.2 FINANCIAL OVERVIEW 128
12.2.3 PRODUCTS OFFERED 129
12.2.4 KEY DEVELOPMENTS 129
12.2.5 SWOT ANALYSIS 129
12.2.6 KEY STRATEGIES 130
12.3 HENKEL AG & CO. KGAA 131
12.3.1 COMPANY OVERVIEW 131
12.3.2 FINANCIAL OVERVIEW 131
12.3.3 PRODUCTS OFFERED 132
12.3.4 KEY DEVELOPMENTS 132
12.3.5 SWOT ANALYSIS 132
12.3.6 KEY STRATEGIES 133
12.4 CRYOPAK 134
12.4.1 COMPANY OVERVIEW 134
12.4.2 FINANCIAL OVERVIEW 134
12.4.3 PRODUCTS OFFERED 134
12.4.4 KEY DEVELOPMENTS 134
12.4.5 SWOT ANALYSIS 135
12.4.6 KEY STRATEGIES 135
12.5 MERCK KGAA 136
12.5.1 COMPANY OVERVIEW 136
12.5.2 FINANCIAL OVERVIEW 137
12.5.3 PRODUCTS OFFERED 137
12.5.4 KEY DEVELOPMENTS 138
12.5.5 SWOT ANALYSIS 138
12.5.6 KEY STRATEGIES 138
12.6 PLUSS ADVANCED TECHNOLOGIES PVT. LTD 139
12.6.1 COMPANY OVERVIEW 139
12.6.2 FINANCIAL OVERVIEW 139
12.6.3 PRODUCTS OFFERED 139
12.6.4 KEY DEVELOPMENTS 140
12.6.5 SWOT ANALYSIS 141
12.6.6 KEY STRATEGIES 141
12.7 PURETEMP 142
12.7.1 COMPANY OVERVIEW 142
12.7.2 FINANCIAL OVERVIEW 142
12.7.3 PRODUCTS OFFERED 142
12.7.4 KEY DEVELOPMENTS 142
12.7.5 SWOT ANALYSIS 143
12.7.6 KEY STRATEGIES 143
12.8 TEAPPCM 144
12.8.1 COMPANY OVERVIEW 144
12.8.2 FINANCIAL OVERVIEW 144
12.8.3 PRODUCTS OFFERED 144
12.8.4 KEY DEVELOPMENTS 144
12.8.5 SWOT ANALYSIS 145
12.8.6 KEY STRATEGIES 145
12.9 RUBITHERM 146
12.9.1 COMPANY OVERVIEW 146
12.9.2 FINANCIAL OVERVIEW 146
12.9.3 PRODUCT OFFERINGS 146
12.9.4 KEY DEVELOPMENTS 147
12.9.5 SWOT ANALYSIS 147
12.9.6 KEY STRATEGIES 147
12.10 PCM PRODUCTS LTD 148
12.10.1 COMPANY OVERVIEW 148
12.10.2 FINANCIAL OVERVIEW 148
12.10.3 PRODUCT OFFERINGS 148
12.10.4 KEY DEVELOPMENTS 149
12.10.5 SWOT ANALYSIS 149
12.10.6 KEY STRATEGIES 149
12.11 COLD CHAIN TECHNOLOGIE 150
12.11.1 COMPANY OVERVIEW 150
12.11.2 FINANCIAL OVERVIEW 150
12.11.3 PRODUCT OFFERINGS 150
12.11.4 KEY DEVELOPMENTS 151
12.11.5 SWOT ANALYSIS 151
12.11.6 KEY STRATEGIES 151
13 APPENDIX 152
13.1 REFERENCES 152
13.2 RELATED REPORTS 153

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
TABLE 3 GLOBAL: CELLULITE TREATMENT MARKET, BY TREATMENT PROCEDURE, 2018–2027 (USD MILLION)
TABLE 4 GLOBAL: CELLULITE TREATMENT MARKET, FOR NON-INVASIVE, BY REGION, 2018–2027 (USD MILLION)
TABLE 5 GLOBAL: CELLULITE TREATMENT MARKET, FOR TOPICAL, BY REGION, 2018–2027 (USD MILLION)
TABLE 6 GLOBAL: CELLULITE TREATMENT MARKET, FOR MINIMALLY INVASIVE, BY REGION, 2018–2027 (USD MILLION)
TABLE 7 GLOBAL: CELLULITE TREATMENT MARKET, FOR OTHERS, BY REGION, 2018–2027 (USD MILLION)
TABLE 8 GLOBAL: CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2018–2027 (USD MILLION)
TABLE 9 GLOBAL: CELLULITE TREATMENT MARKET, FOR SOFT CELLULITE, BY REGION, 2018–2027 (USD MILLION)
TABLE 10 GLOBAL: CELLULITE TREATMENT MARKET, FOR HARD CELLULITE, BY REGION, 2018–2027 (USD MILLION)
TABLE 11 GLOBAL: CELLULITE TREATMENT MARKET, FOR EDEMATOUS CELLULITE, BY REGION, 2018–2027 (USD MILLION)
TABLE 12 GLOBAL: CELLULITE TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 13 GLOBAL: CELLULITE TREATMENT MARKET, FOR HOSPITALS, BY REGION, 2018–2027 (USD MILLION)
TABLE 14 GLOBAL: CELLULITE TREATMENT MARKET, FOR SPECIALISED DERMATOLOGY CLINICS, BY REGION, 2018–2027 (USD MILLION)
TABLE 15 GLOBAL: CELLULITE TREATMENT MARKET, FOR AMBULATORY SURGICAL CENTERS, BY REGION, 2018–2027 (USD MILLION)
TABLE 16 GLOBAL: CELLULITE TREATMENT MARKET, FOR OTHERS, BY REGION, 2018–2027 (USD MILLION)
TABLE 17 GLOBAL: CELLULITE TREATMENT MARKET, BY REGION, 2018–2027 (USD MILLION)
TABLE 18 NORTH AMERICA: CELLULITE TREATMENT MARKET, BY COUNTRY, 2018–2027 (USD MILLION)
TABLE 19 NORTH AMERICA: CELLULITE TREATMENT MARKET, BY TREATMENT PROCEDURE, 2018–2027 (USD MILLION)
TABLE 20 NORTH AMERICA: CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2018–2027 (USD MILLION)
TABLE 21 NORTH AMERICA: CELLULITE TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 22 US: CELLULITE TREATMENT MARKET, BY TREATMENT PROCEDURE, 2018–2027 (USD MILLION)
TABLE 23 US: CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2018–2027 (USD MILLION)
TABLE 24 US: CELLULITE TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 25 CANADA: CELLULITE TREATMENT MARKET, BY TREATMENT PROCEDURE, 2018–2027 (USD MILLION)
TABLE 26 CANADA: CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2018–2027 (USD MILLION)
TABLE 27 CANADA: CELLULITE TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 28 EUROPE: CELLULITE TREATMENT MARKET, BY COUNTRY, 2018–2027 (USD MILLION)
TABLE 29 EUROPE: CELLULITE TREATMENT MARKET, BY TREATMENT PROCEDURE, 2018–2027 (USD MILLION)
TABLE 30 EUROPE: CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2018–2027 (USD MILLION)
TABLE 31 EUROPE: CELLULITE TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 32 GERMANY: CELLULITE TREATMENT MARKET, BY TREATMENT PROCEDURE, 2018–2027 (USD MILLION)
TABLE 33 GERMANY: CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2018–2027 (USD MILLION)
TABLE 34 GERMANY: CELLULITE TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 35 UK: CELLULITE TREATMENT MARKET, BY TREATMENT PROCEDURE, 2018–2027 (USD MILLION)
TABLE 36 UK: CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2018–2027 (USD MILLION)
TABLE 37 UK: CELLULITE TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 38 FRANCE: CELLULITE TREATMENT MARKET, BY TREATMENT PROCEDURE, 2018–2027 (USD MILLION)
TABLE 39 FRANCE: CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2018–2027 (USD MILLION)
TABLE 40 FRANCE: CELLULITE TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 41 ITALY: CELLULITE TREATMENT MARKET, BY TREATMENT PROCEDURE, 2018–2027 (USD MILLION)
TABLE 42 ITALY: CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2018–2027 (USD MILLION)
TABLE 43 ITALY: CELLULITE TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 44 SPAIN: CELLULITE TREATMENT MARKET, BY TREATMENT PROCEDURE, 2018–2027 (USD MILLION)
TABLE 45 SPAIN: CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2018–2027 (USD MILLION)
TABLE 46 SPAIN: CELLULITE TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 47 REST OF EUROPE: CELLULITE TREATMENT MARKET, BY TREATMENT PROCEDURE, 2018–2027 (USD MILLION)
TABLE 48 REST OF EUROPE: CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2018–2027 (USD MILLION)
TABLE 49 REST OF EUROPE: CELLULITE TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 50 ASIA PACIFIC: CELLULITE TREATMENT MARKET, BY COUNTRY, 2018–2027 (USD MILLION)
TABLE 51 ASIA PACIFIC: CELLULITE TREATMENT MARKET, BY TREATMENT PROCEDURE, 2018–2027 (USD MILLION)
TABLE 52 ASIA PACIFIC: CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2018–2027 (USD MILLION)
TABLE 53 ASIA PACIFIC: CELLULITE TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 54 CHINA: CELLULITE TREATMENT MARKET, BY TREATMENT PROCEDURE, 2018–2027 (USD MILLION)
TABLE 55 CHINA: CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2018–2027 (USD MILLION)
TABLE 56 CHINA: CELLULITE TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 57 JAPAN: CELLULITE TREATMENT MARKET, BY TREATMENT PROCEDURE, 2018–2027 (USD MILLION)
TABLE 58 JAPAN: CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2018–2027 (USD MILLION)
TABLE 59 JAPAN: CELLULITE TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 60 INDIA: CELLULITE TREATMENT MARKET, BY TREATMENT PROCEDURE, 2018–2027 (USD MILLION)
TABLE 61 INDIA: CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2018–2027 (USD MILLION)
TABLE 62 INDIA: CELLULITE TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 63 SOUTH KOREA: CELLULITE TREATMENT MARKET, BY TREATMENT PROCEDURE, 2018–2027 (USD MILLION)
TABLE 64 SOUTH KOREA: CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2018–2027 (USD MILLION)
TABLE 65 SOUTH KOREA: CELLULITE TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 66 AUSTRALIA: CELLULITE TREATMENT MARKET, BY TREATMENT PROCEDURE, 2018–2027 (USD MILLION)
TABLE 67 AUSTRALIA: CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2018–2027 (USD MILLION)
TABLE 68 AUSTRALIA: CELLULITE TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 69 REST OF ASIA PACIFIC: CELLULITE TREATMENT MARKET, BY TREATMENT PROCEDURE, 2018–2027 (USD MILLION)
TABLE 70 REST OF ASIA PACIFIC: CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2018–2027 (USD MILLION)
TABLE 71 REST OF ASIA PACIFIC: CELLULITE TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 72 REST OF THE WORLD: CELLULITE TREATMENT MARKET, BY COUNTRY, 2018–2027 (USD MILLION)
TABLE 73 REST OF THE WORLD: CELLULITE TREATMENT MARKET, BY TREATMENT PROCEDURE, 2018–2027 (USD MILLION)
TABLE 74 REST OF THE WORLD: CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2018–2027 (USD MILLION)
TABLE 75 REST OF THE WORLD: CELLULITE TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 76 MIDDLE EAST: CELLULITE TREATMENT MARKET, BY TREATMENT PROCEDURE, 2018–2027 (USD MILLION)
TABLE 77 MIDDLE EAST: CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2018–2027 (USD MILLION)
TABLE 78 MIDDLE EAST: CELLULITE TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 79 AFRICA: CELLULITE TREATMENT MARKET, BY TREATMENT PROCEDURE, 2018–2027 (USD MILLION)
TABLE 80 AFRICA: CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2018–2027 (USD MILLION)
TABLE 81 AFRICA: CELLULITE TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 82 LATIN AMERICA: CELLULITE TREATMENT MARKET, BY TREATMENT PROCEDURE, 2018–2027 (USD MILLION)
TABLE 83 LATIN AMERICA: CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2018–2027 (USD MILLION)
TABLE 84 LATIN AMERICA: CELLULITE TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 85 MAJOR PLAYERS IN THE GLOBAL CELLULITE TREATMENT MARKET
TABLE 86 MOST ACTIVE PLAYER IN THE GLOBAL CELLULITE TREATMENT MARKET
TABLE 87 PRODUCT LAUNCH/PRODUCT APPROVAL
TABLE 88 HOLOGIC, INC: PRODUCTS/SERVICES OFFERED
TABLE 89 NUBWAY CO.LTD.: PRODUCTS/SERVICES OFFERED
TABLE 90 MERZ PHARMA GMBH & CO. KGAA: PRODUCTS/SERVICES OFFERED
TABLE 91 ZIMMER AESTHETICS: PRODUCTS/SERVICES OFFERED
TABLE 92 CYMEDICS: PRODUCTS/SERVICES OFFERED
TABLE 93 CYNOSURE, LLC: PRODUCTS/SERVICES OFFERED
TABLE 94 INCELER MEDIKAL CO. LTD.: PRODUCTS/SERVICES OFFERED
TABLE 95 CANDELA MEDICAL: PRODUCTS/SERVICES OFFERED
TABLE 96 CUTERA, INC.: PRODUCTS/SERVICES OFFERED
TABLE 97 CUTERA, INC.: KEY DEVELOPMENTS
TABLE 98 BEIJING SINCOHEREN S & T DEVELOPMENT CO., LTD.: PRODUCTS/SERVICES OFFERED

LIST OF FIGURES

FIGURE 1 MARKET SYNOPSIS
FIGURE 2 MARKET STRUCTURE: GLOBAL CELLULITE TREATMENT MARKET
FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES
FIGURE 4 MARKET DYNAMICS: GLOBAL CELLULITE TREATMENT MARKET
FIGURE 5 DRIVER IMPACT ANALYSIS
FIGURE 6 RESTRAINT IMPACT ANALYSIS
FIGURE 7 VALUE CHAIN ANALYSIS: GLOBAL CELLULITE TREATMENT MARKET
FIGURE 8 PORTER’S FIVE FORCES ANALYSIS: GLOBAL CELLULITE TREATMENT MARKET
FIGURE 9 GLOBAL CELLULITE TREATMENT MARKET, BY TREATMENT PROCEDURE, 2020 & 2027 (USD MILLION)
FIGURE 10 GLOBAL: CELLULITE TREATMENT MARKET, CELLULITE TYPE, 2020 & 2027 (USD MILLION)
FIGURE 11 GLOBAL: CELLULITE TREATMENT MARKET, END USER, 2020 & 2027 (USD MILLION)
FIGURE 12 GLOBAL: CELLULITE TREATMENT MARKET, BY REGION 2020 & 2027 (USD MILLION)
FIGURE 13 GLOBAL: CELLULITE TREATMENT MARKET SHARE (%), BY REGION, 2020
FIGURE 14 NORTH AMERICA: CELLULITE TREATMENT MARKET SHARE (%), BY COUNTRY 2020
FIGURE 15 EUROPE: CELLULITE TREATMENT MARKET SHARE (%), BY COUNTRY 2020
FIGURE 16 ASIA PACIFIC: CELLULITE TREATMENT MARKET SHARE (%), BY COUNTRY 2020
FIGURE 17 REST OF THE WORLD: CELLULITE TREATMENT MARKET SHARE (%), BY COUNTRY 2020
FIGURE 18 BENCHMARKING OF MAJOR COMPETITORS
FIGURE 19 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL CELLULITE TREATMENT MARKET
FIGURE 20 HOLOGIC, INC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 21 HOLOGIC, INC: SWOT ANALYSIS
FIGURE 22 NUBWAY CO.LTD.: SWOT ANALYSIS
FIGURE 23 MERZ PHARMA GMBH & CO. KGAA: SWOT ANALYSIS
FIGURE 24 ZIMMER AESTHETICS: SWOT ANALYSIS
FIGURE 25 CYMEDICS: SWOT ANALYSIS